CLINICAL TRIALS PROFILE FOR CHOLESTYRAMINE LIGHT

All Clinical Trials for CHOLESTYRAMINE LIGHT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004266 ↗	Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes	Completed	Hennepin County Medical Center, Minneapolis	Phase 3	1993-08-01	OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
NCT00000463 ↗	Post Coronary Artery Bypass Graft (CABG) Study	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1987-04-01	To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.
NCT00000461 ↗	Harvard Atherosclerosis Reversibility Project (HARP)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1986-12-01	To determine by sequential coronary arteriography whether a lipid-lowering diet with and without lipid-lowering drugs could reverse coronary artery disease in normocholesterolemic patients. Also, to test whether fish oil supplements could improve human coronary atherosclerosis. Finally, to determine the effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. At least three clinical trials were conducted.
NCT00000488 ↗	Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1973-06-01	To determine whether reduction of cholesterol by drug therapy significantly lowered the atherosclerotic coronary heart disease rate in a group of hypercholesterolemic but otherwise healthy men. Total dollars spent on the CPPT from June 1973 were $142,250,000. We do not have a year-by-year breakdown.
NCT00000594 ↗	NHLBI Type II Coronary Intervention Study	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1971-11-01	To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography.

Clinical Trial Conditions for CHOLESTYRAMINE LIGHT

Condition Name

Condition Name for CHOLESTYRAMINE LIGHT
Intervention	Trials
Cardiovascular Diseases	4
Myocardial Ischemia	4
Coronary Disease	4
Heart Diseases	4

Condition MeSH

Condition MeSH for CHOLESTYRAMINE LIGHT
Intervention	Trials
Hypercholesterolemia	5
Coronary Artery Disease	4
Hyperlipoproteinemia Type II	4
Cardiovascular Diseases	4

Clinical Trial Locations for CHOLESTYRAMINE LIGHT

Trials by Country

+

−

Trials by Country for CHOLESTYRAMINE LIGHT
Location	Trials
United States	44
Germany	9
Canada	5
Netherlands	5
Brazil	4

Trials by US State

+

−

Trials by US State for CHOLESTYRAMINE LIGHT
Location	Trials
North Carolina	4
Missouri	4
Ohio	3
California	3
Florida	2

Clinical Trial Progress for CHOLESTYRAMINE LIGHT

Clinical Trial Phase

Clinical Trial Phase for CHOLESTYRAMINE LIGHT
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	10
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for CHOLESTYRAMINE LIGHT
Clinical Trial Phase	Trials
Completed	27
Recruiting	6
Unknown status	2

Clinical Trial Sponsors for CHOLESTYRAMINE LIGHT

Sponsor Name

Sponsor Name for CHOLESTYRAMINE LIGHT
Sponsor	Trials
Sanofi	7
National Heart, Lung, and Blood Institute (NHLBI)	4
Regeneron Pharmaceuticals	3

Sponsor Type

Sponsor Type for CHOLESTYRAMINE LIGHT
Sponsor	Trials
Other	38
Industry	21
NIH	8

Cholestyramine Light: Clinical Trials, Market Analysis, and Projections

Introduction to Cholestyramine Light

Cholestyramine Light, a bile acid sequestrant, has been a staple in the management of hypercholesterolemia and certain liver conditions for over 50 years. This medication works by binding to bile acids in the intestines, preventing their reabsorption, and thereby reducing cholesterol levels in the blood[2][4].

Clinical Trials and Efficacy

Clinical trials have consistently shown the efficacy of Cholestyramine Light in managing hypercholesterolemia. A study comparing the new low-calorie formulation (Questran Light) to the traditional formulation (Questran) found that both formulations were equally effective in maintaining lowered plasma cholesterol levels. The study involved 61 men with hypercholesterolemia and demonstrated no statistically significant differences in lipid/lipoprotein levels between the two groups[3].

Another key aspect of clinical trials involves the monitoring of adverse effects and interactions. Cholestyramine Light is known to interact with various drugs, including HMG-CoA reductase inhibitors, warfarin, and thyroid drugs, among others. Patients are advised to take other medications at least 1-2 hours before or 4-6 hours after Cholestyramine Light to avoid impeding their absorption[1][4].

Market Analysis

The Cholestyramine market is poised for significant growth driven by several key factors:

Increasing Demand for Cholesterol-Lowering Drugs

Cardiovascular diseases remain the leading cause of death worldwide, and high cholesterol is a major risk factor. As a result, the demand for cholesterol-lowering medications, including Cholestyramine, is expected to rise as healthcare providers focus on preventing and managing high cholesterol levels[2].

Global Aging Population

The global aging population is another key driver of the Cholestyramine market's growth. This demographic shift is expected to drive the demand for cholesterol-lowering drugs as part of comprehensive heart health management[2].

Emphasis on Preventive Healthcare

There is a growing global emphasis on preventive healthcare, with more individuals seeking ways to manage their cholesterol levels before they develop cardiovascular issues. This has led to an increased demand for medications like Cholestyramine[2].

Market Projections

Global Market Size and Growth

The Cholestyramine market size was estimated at USD 186.60 million in 2023 and is expected to reach USD 196.08 million in 2024, with a projected Compound Annual Growth Rate (CAGR) of 5.42% to reach USD 270.03 million by 2030[5].

Regional Markets

• North America: Remains the largest market for Cholestyramine, driven by a high prevalence of cardiovascular diseases and a well-established healthcare infrastructure[2].
• Europe: The market is experiencing steady growth, supported by public health campaigns and healthcare policies promoting cholesterol management. There is a strong demand for generic Cholestyramine products[2].
• Asia-Pacific: Expected to witness significant growth due to rising healthcare awareness, improving healthcare infrastructure, and increasing disposable incomes in countries like China and India[2].

Business and Investment Opportunities

The rising demand for cholesterol-lowering drugs presents significant business and investment opportunities within the Cholestyramine market. Pharmaceutical companies are forming strategic partnerships to expand the distribution of Cholestyramine and develop new treatment options. These partnerships are crucial for reaching a broader patient base and ensuring that Cholestyramine becomes a widely accessible treatment option[2].

Challenges and Future Outlook

Despite the growth prospects, the Cholestyramine market faces challenges such as the emergence of alternative treatments with fewer side effects and generic competition, which can lower market profitability. Stringent regulatory guidelines also pose barriers to new market entrants[5].

Innovations and Improvements

The introduction of new formulations and improvements in patient adherence to treatment are expected to further fuel growth. Innovations in drug formulations and healthcare technologies will continue to make Cholestyramine a critical tool in managing high cholesterol levels[2].

Key Takeaways

• Cholestyramine Light is effective in managing hypercholesterolemia and certain liver conditions.
• Clinical trials have shown its efficacy comparable to traditional formulations.
• The market is driven by increasing demand for cholesterol-lowering drugs, an aging population, and a focus on preventive healthcare.
• The global market is projected to grow significantly, with North America, Europe, and Asia-Pacific being key regions.
• Business and investment opportunities are substantial, but the market faces challenges from alternative treatments and regulatory barriers.

Frequently Asked Questions (FAQs)

1. What is Cholestyramine Light used for?

Cholestyramine Light is used to lower high cholesterol levels in the blood and to treat certain types of itching and diarrhea associated with liver disease[1][4].

2. How does Cholestyramine Light work?

It works by binding to bile acids in the intestines and preventing their reabsorption, which forces the liver to use more cholesterol to produce new bile acids, thereby lowering overall cholesterol levels in the blood[2][4].

3. What are the common side effects of Cholestyramine Light?

Common side effects include constipation, fecal impaction, aggravation of hemorrhoids, GI disturbances, and deficiencies in vitamins A, D, K, or folic acid[1][4].

4. Can Cholestyramine Light interact with other medications?

Yes, Cholestyramine Light can interact with various medications, including HMG-CoA reductase inhibitors, warfarin, and thyroid drugs. Patients should take other medications at least 1-2 hours before or 4-6 hours after Cholestyramine Light[1][4].

5. What is the projected market size for Cholestyramine by 2030?

The Cholestyramine market is expected to reach USD 270.03 million by 2030, growing at a CAGR of 5.42%[5].

Cited Sources:

1. eMPR.com: Cholestyramine Light Prescription & Dosage Information.
2. MarketResearchIntellect.com: Cholestyramine Market Set for Growth as Demand for Cholesterol-Lowering Drugs Rises.
3. PubMed: Comparison of the efficacy of Questran Light, a new low-calorie cholestyramine formulation.
4. Health Canada: PRODUCT MONOGRAPH PrCHOLESTYRAMINE-ODAN Light.
5. 360iResearch: Cholestyramine Market Size & Share 2025-2030.